Skip to content
Research Article Open access CC BY 4.0

Convalescent Plasma Infusion in Italian Hospitalized Patients with Severe COVID 19 Pneumonia: Evaluation of Late Mortality Associated Factors

Gianluca Gessoni, Giovanni Roveroni, Lauretta Moro, Michela Pivetta, Michele Tessarin, Domenico Bagnara, Sara Valverde, Rossi Carla, Coluccia Enza, Collodel Luca, Roberto Valle, Giovanni Carretta

International Blood Research & Reviews · pp. 12–33 · Published 17 Mar 2023

10.9734/ibrr/2023/v14i2302

Abstract

Background: This was a single center prospective study about factors related with mortality in hospitalized patients with severe COVID-19 pneumonia treated with convalescent plasma (CCP) infusion in Venice Prefecture. Methods: In this study were enrolled all the (376) consecutive hospitalized patients with severe COVID-19 pneumonia treated with CCP observed from 30/04/2020 to 31/10/2021.  At hospital admission, in order to evaluate correlation with prognosis, study recorded demographic data, clinical data, presence of co morbidities, Rx findings, laboratory results.  The endpoint was mortality at 30 days. Results: Using multivariate analysis, considering demographic data and co morbidities four variables emerged as significant independent predictors of 30-day mortality:  age>70 years, tobacco smoke, obesity (BMI>30), Diabetes. Considering Patients’ clinical characteristics at hospital admission two variables emerged as significant independent predictors of 30-day mortality in this cohort of hospitalized patients with severe COVID-19 Pneumonia: PaO2/FiO2 ratio under 200 and lungs imaging with a score >3. Discussion: Late mortality was investigated in a series of consecutive, hospitalized, patients with severe COVID-19. We therefore believe that any influence linked to the level of expertise of the clinical staff and available technology was minimal. Furthermore, we also tried to reduce, as much as possible, the variables related CCP infusion using plasma with a neutralizing antibody titer> 80 and a standardized dose: a 200 mL unit per day for three consecutive days. Moreover, using both a univariate and multivariate analytical approach, numerous demographic variables were considered, relating to comorbidities, all clinical characteristics, to laboratory data; correlating them with mortality at 30 days.

COVID-19 convalescent plasma mortality pneumonia risk factors

References (36)

  1. 1 Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [DOI]
  2. 2 CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) [DOI]
  3. 3 Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis [DOI]
  4. 4 Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy [DOI]
  5. 5 The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? [DOI]
  6. 6 Coagulation abnormalities and thrombosis in patients with COVID-19 [DOI]
  7. 7 COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis [DOI]
  8. 8 D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19 [DOI]
  9. 9 The SOFA score—development, utility and challenges of accurate assessment in clinical trials [DOI]
  10. 10 A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia [DOI]
  11. 11 C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early [DOI]
  12. 12 Association Between Hypoxemia and Mortality in Patients With COVID-19 [DOI]
  13. 13 Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea [DOI]
  14. 14 Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 [DOI]
  15. 15 Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV [DOI]
  16. 16 Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients [DOI]
  17. 17 The value of clinical parameters in predicting the severity of COVID‐19 [DOI]
  18. 18 Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial [DOI]
  19. 19 Drug Evaluation during the Covid-19 Pandemic [DOI]
  20. 20 Chest X-ray severity index as a predictor of in-hospital mortality in coronavirus disease 2019: A study of 302 patients from Italy [DOI]
  21. 21 Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID‐19 patients: A meta‐regression and decision tree analysis [DOI]
  22. 22 The prognostic value of the SOFA score in patients with COVID-19 [DOI]
  23. 23 Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality [DOI]
  24. 24 Convalescent plasma may be a possible treatment for COVID-19: A systematic review [DOI]
  25. 25 COVID-19 Clinical Guidance For the Cardiovascular Care Team
  26. 26 Operational protocol for donation of anti‐COVID‐19 convalescent plasma in Italy [DOI]
  27. 27 CT-derived pulmonary vascular metrics and clinical outcome in COVID-19 patients [DOI]
  28. 28 Cardiac troponins predict mortality in patients with COVID-19: A meta-analysis of adjusted risk estimates [DOI]
  29. 29 Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis [DOI]
  30. 30 Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry [DOI]
  31. 31 Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience [DOI]
  32. 32 Elevated Cardiac Troponin I Is Associated with Poor Outcomes in COVID-19 Patients at an Academic Medical Center in Midwestern USA [DOI]
  33. 33 Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis [DOI]
  34. 34 Critically Ill vs. Non-Critically Ill Patients With COVID-19 Pneumonia: Clinical Features, Laboratory Findings, and Prediction [DOI]
  35. 35 Epidemiology of Coronavirus Disease Outbreak: The Italian Trends [DOI]
  36. 36 EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

52

Page views

0

PDF downloads

14

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.